ライフサイエンスコーパス: aminocoumarin

1 tethered by a tetraene diester linker to an aminocoumarin.

2 to NovH or on the subsequently released free aminocoumarin.

3 L-tyrosyl-L-valyl-L-aspartic acid 4-methyl-7-aminocoumarin.

4 s derived from beta-lactams, macrolides, and aminocoumarins.

5 Libraries of aminocoumarin analogues have been generated by in vivo f

6 nolignol analogs gamma-linked to fluorogenic aminocoumarin and nitrobenzofuran dyes were synthesized

7 ding pockets that separately accommodate the aminocoumarin and polyketide moieties of the antibiotic.

8 thetases which construct amide bonds between aminocoumarins and various acyl moieties.

9 olides, 2 ionophores, 2 diaminopyimidines, 1 aminocoumarin, and 1 lincosamide).

10 yrase inhibitors such as fluoroquinolone and aminocoumarin antibacterials.

11 penultimate step in the biosynthesis of the aminocoumarin antibiotic novobiocin.

12 the specific timing of C-methylation in the aminocoumarin antibiotic pathways is established.

13 The aminocoumarin antibiotics clorobiocin and coumermycin A(

14 he 5-methyl-2-pyrrolylcarbonyl moiety of the aminocoumarin antibiotics clorobiocin and coumermycin A1

15 The biosynthesis of aminocoumarin antibiotics involves the action of amide s

16 During the biosynthesis of the streptomycete aminocoumarin antibiotics novobiocin and the dimeric cou

17 The aminocoumarin antibiotics novobiocin, clorobiocin, and c

18 that the plant is sensitive to quinolone and aminocoumarin antibiotics, compounds that target DNA gyr

19 e is indeed the target for the quinolone and aminocoumarin antibiotics.

20 dem to create additional variants of dimeric aminocoumarin antibiotics.

21 The aminocoumarin class of antibiotics, exemplified by novob

22 The caging group 7-N,N-diethyl aminocoumarin (DECM) was used to cage the gamma-carboxyl

23 rin 461 (C461), both belong to a family of 7-aminocoumarin dyes that have distinctive fluorescence li

24 Coumermycin A(1) is a member of the aminocoumarin family of antibiotics.

25 cin A(1), the phenolic hydroxyl group of the aminocoumarin in simocyclinone is not glycosylated with

26 residues in the MHC peptide binding site and aminocoumarin-labeled peptides, we measured real-time ki

27 tes were identified upon screening an N-acyl aminocoumarin library.

28 terminal subunit of yeast TBP (yTBPc) and an aminocoumarin moiety appended either upstream or downstr

29 ers in the functional dimeric unit, with the aminocoumarin moiety of SD8 buried in the protein core,

30 The bicyclic coumarin ring in the aminocoumarin natural product antibiotics that target ba

31 say monitors the decrease in fluorescence of aminocoumarins on acylation.

32 -glutamic-L-valyl-L-aspartic acid 4-methyl-7-aminocoumarin or acetyl-L-tyrosyl-L-valyl-L-aspartic aci

33 Similar experiments on Indo-1, NADH, and aminocoumarin produced similar results and suggest that

34 Escherichia coli and shown to act after the aminocoumarin ring has been constructed by prior action

35 oups installed on the noviosyl moiety of the aminocoumarin scaffold.

36 at predominates in the subsequently cyclized aminocoumarin scaffold.

37 solid-phase synthesis of a library of N-acyl aminocoumarin substrates and the screening procedure to

38 ence-based assay; (ii) the identified N-acyl aminocoumarin substrates are optimized by rapid analog s

39 cence-based assay, (2) the identified N-acyl aminocoumarin substrates are optimized by rapid analogue

40 NovL ligates the aminocoumarin to prenylhydroxybenzoate to yield novobioc

41 akes the bis-amide by tandem ligation of two aminocoumarins to a dicarboxypyrrole.

42 e CouL for mono- and bisamide formation with aminocoumarins to provide substrates for the glycosyltra

43 L-tyrosyl-L-valyl-L-aspartic acid 4-methyl-7-aminocoumarin was resistant to cleavage activity.

44 assisted hybridization strategy, a number of aminocoumarins were designed, prepared, and tested as mo

45 into inhibitors by direct replacement of the aminocoumarin with known mechanism-based pharmacophores.

46 d to inhibitors by direct replacement of the aminocoumarin with known mechanism-based pharmacophores.

47 ists of three steps: (1) a library of N-acyl aminocoumarins with diverse, low molecular weight N-acyl

48 ists of three steps: (i) a library of N-acyl aminocoumarins with diverse, low-molecular-weight N-acyl

49 -glutamic-L-valyl-L-aspartic acid 4-methyl-7-aminocoumarin within 6 hr following etoposide addition,